Skip to main content
Yantai Zhenghai Bio-Tech Co., Ltd. logo

Yantai Zhenghai Bio-Tech Co., Ltd. — Investor Relations & Filings

Ticker · 300653 ISIN · CNE100002NZ1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 970 across all filing types
Latest filing 2020-04-09 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300653

About Yantai Zhenghai Bio-Tech Co., Ltd.

https://www.zhbio.com

Yantai Zhenghai Bio-Tech Co., Ltd. specializes in the research, development, production, and sale of regenerative medicine materials. The company focuses on tissue engineering and biomaterials to provide solutions for clinical repair and functional reconstruction. Its core product portfolio includes the Heal-All oral repair membrane, absorbable hard cerebral (spinal) membrane patches, and skin repair membranes. These products are widely utilized in stomatology, neurosurgery, and orthopedics. The company leverages advanced processing technologies to ensure biocompatibility and safety in its medical devices. By integrating research with clinical needs, it develops innovative bone repair materials and other biological scaffolds designed to facilitate natural tissue regeneration.

Recent filings

Filing Released Lang Actions
控股股东及其他关联方占用资金情况审核报告
Audit Report / Information Classification · 95% confidence The document is an audit report issued by a certified public accounting firm regarding the company's related party transactions, specifically the use of funds by controlling shareholders and other related parties for the fiscal year ending December 31, 2019. It includes audit opinions, basis of the audit, responsibilities of management and auditors, and a detailed summary table of the related party fund usage. The document is titled as an audit report and contains substantive financial data and audit conclusions. It is not a full annual report, nor is it a brief announcement or certification. Therefore, it fits the category of an Audit Report / Information (AR). The document length is 3256 characters, which is consistent with a standalone audit report rather than a full annual report or a short announcement. FY 2019
2020-04-09 Chinese
广发证券股份有限公司关于公司2019年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (广发证券股份有限公司) regarding the 2019 internal control self-evaluation report of 烟台正海生物科技股份有限公司. It discusses the scope, standards, and results of internal control evaluation, including financial and non-financial control defects, and concludes on the effectiveness of internal controls. The document is not the internal control report itself but an audit or verification opinion on that report. It contains detailed analysis and professional opinion on internal controls, which aligns with the nature of an Audit Report / Information (AR). It is not an Annual Report (10-K), nor a simple announcement or certification. The length and content confirm it is a standalone audit-related report, not a brief announcement or a regulatory filing. Therefore, the correct classification is AR with high confidence. FY 2019
2020-04-09 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制鉴证报告' which translates to 'Internal Control Assurance Report'. It is issued by a certified public accounting firm and addresses the effectiveness of internal controls related to financial reporting as of December 31, 2019. The content includes the responsibilities of management and auditors, the scope of the assurance engagement, inherent limitations of internal control, and the auditor's opinion on the effectiveness of internal controls. The document is a standalone audit-related report focusing on internal control effectiveness, not a full annual report or financial statement. It does not contain financial statements or management discussion but is an audit assurance report on internal controls. Therefore, it fits the category of Audit Report / Information (AR). The document length is 1688 characters, which is consistent with a standalone audit report rather than a full annual report or other filings. FY 2019
2020-04-09 Chinese
关于聘任副总经理的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a new deputy general manager (副总经理) at the company 烟台正海生物科技股份有限公司. It includes details about the board meeting approving the appointment, the candidate's resume, and compliance statements. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to any report publication. The content clearly relates to management changes, specifically senior management appointment. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused solely on this announcement, reinforcing this classification.
2020-04-09 Chinese
关于变更注册资本并修订《公司章程》的公告
Regulatory Filings Classification · 95% confidence The document is titled as an announcement regarding the change in registered capital and the revision of the company's articles of association. It details the board meeting resolutions, the proposed changes in share capital, and amendments to the company charter, which require shareholder approval. The document is relatively short (2189 characters) and serves as a formal public announcement of these corporate governance changes rather than the full legal or financial report itself. There is no detailed financial statement or comprehensive report content, only a notice of changes and procedural steps. Therefore, this fits the category of a Regulatory Filing (RNS) as it is a formal announcement of corporate changes without the full report or detailed financial data.
2020-04-09 Chinese
关于使用闲置募集资金及自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is titled as a "现金管理进展公告" which translates to "Cash Management Progress Announcement." It details the company's use of idle raised funds and own funds for cash management, including specific financial products purchased, approval procedures, risk control measures, and the impact on the company. The document includes tables of financial product purchases, expected yields, and dates, but it is not a comprehensive financial report or earnings release. It is an announcement about the progress and status of cash management activities rather than a full financial report or regulatory filing. The document length is about 6,496 characters, which is substantial but the content is focused on cash management updates and not a full report. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including cash management activities using idle funds.
2020-04-09 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.